H.C. Wainwright initiated coverage on Virax Biolabs Group Limited (NASDAQ:VRAX), a U.K.-based company focused on detecting ...

2024: Leica Microsystems introduced TauSTED Xtend, a breakthrough in STED microscopy. This new approach allows for extended ...

Virax Biolabs begins enrolling patients in clinical study assessing T cell dysfunction in post-acute infection syndromes: London Wednesday, March 19, 2025, 16:00 Hrs [IST] Virax B ...

Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the ...

The latest update is out from Virax Biolabs Group Ltd. Class A ( ($VRAX) ). On March 18, 2025, Virax Biolabs Group Limited announced the ...

Virax Biolabs (VRAX) has started enrolling patients into its United Kingdom based, multi-center clinical study. Conducted in collaboration with ...

Using an unbiased approach, this important study discovered a role of Ezh2 in the differentiation of granule neuron precursors, the cell of origin for Shh group of medulloblastoma. Furthermore, the ...

LONDON - Virax Biolabs Group Limited (NASDAQ:VRAX), a micro-cap biotechnology company with a market value of $6.39 million specializing in immune response detection and viral disease diagnosis, has ...

Bris­tol My­ers Squibb will ac­quire its CAR-T cell ther­a­py col­lab­o­ra­tor 2sev­en­ty bio for $286 mil­lion in cash, the com­pa­nies said late Mon­day evening.

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling itself to partner Bristol Myers Squibb. Bristol Myers has agreed to buy out ...

idecabtagene vicleucel (ide-cel), in multiple myeloma and continued development of its own cell therapy pipeline. Abecma is being jointly developed and commercialized in the U.S. as part of a co ...